The Latest Analyst Ratings for CRISPR Therapeutics
Portfolio Pulse from Benzinga Insights
CRISPR Therapeutics (NASDAQ:CRSP) received 7 analyst ratings in the last quarter with an average price target of $72.71, representing an upside from the current price of $70.7. The average price target has increased by 17.27% from the previous target of $62.00. The ratings included 4 bullish, 1 somewhat bullish, 1 indifferent, and 1 somewhat bearish, with no bearish ratings.
December 05, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics has a positive outlook from analysts with an average price target of $72.71, suggesting a potential upside from the current price of $70.7.
The increase in the average price target and the predominance of bullish over bearish ratings indicate a positive sentiment among analysts, which could lead to a short-term increase in CRISPR Therapeutics' stock price. However, as analyst ratings are subject to human error and are not guarantees of performance, the confidence level is not at the maximum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100